In international news, Wegovy maker Novo Nordisk ... a voluntary offer for all of its shares. PK already owns 21.8% of MAS indirectly, and it has offered the equivalent of 85 euro cents per share for ...

Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

What happened to 23andMe? Here's a look at its history from launch to bankruptcy and acquisition by Regeneron.

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

The president’s Middle East visit produced multibillion-dollar technology investments by the Saudis and Emiratis. But they ...

Supply constraints have meant that the drug appears on the FDA's shortage list, which opens the door for compounding pharmacies to offer versions of the drug to patients. Last year, Novo Nordisk ...

(Reuters) -Drugmaker Regeneron Pharmaceuticals is acquiring majority assets of bankrupt genetic testing firm 23andMe Holding for $256 million. The once-sizzling DNA-testing startup filed for ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

In its first-quarter 2025 investor letter, Polen Focus Growth Strategy highlighted stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and development ...